Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Globe Newswire • about 2 months agoWOBURN, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic...